Advertisement

Topics

Companies Related to "Curtana granted Orphan designation gliomas treatment" [Most Relevant Company Matches] RSS

05:18 EST 16th December 2018 | BioPortfolio

Here are the most relevant search results for "Curtana granted Orphan designation gliomas treatment" found in our extensive corporate database of over 50,000 company records.

Showing "Curtana granted Orphan designation gliomas treatment" Companies 1–25 of 3,500+

Extremely Relevant

NEONC Technologies, Inc.

NEONC Technologies, Inc. is an early-stage biotechnology company focused on developing new drugs using intranasal brain delivery. The Company’s lead compound is NEO100, a novel, highly purified form of the monoterpene perillyl alcohol under development for treatment of deadly brain disease known as glioblastoma multiforme. NEONC has established a robu...


Relevant

Gentium S.p.A.

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan ...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...


EntreMed, Inc.

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and antiinflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. Panzem® (2-methoxyestradiol or 2ME2), one of t...

AcuityBio Inc. and Cook Biotech Inc.

AcuityBio has developed a platform technology for localized, sustained, safe drug-delivery to be used in the prevention of post-surgical lung cancer recurrence. ABC103 combines approved/ cleared surgical staple-line buttress, drug eluting polymers and a chemotherapeutic drug, paclitaxel). ABC103 has been granted US FDA orphan drug designation for this indi...

Emmaus Life Sciences, Inc.

Emmaus Life Sciences is dedicated to the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease and sickle beta-0 thalassemia was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The therapy has Orphan D...

Tercica

Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to develop and commercialize therapeutics for growth and other endocrine disorders. In January 2006, less than four years after Tercica was founded, we commercially launched Increlex™ (mecasermin [rDNA ...

AOP Orphan Pharmaceuticals AG

AOP Orphan is a multinational company with headquarters in Vienna, Austria, focusing on clinical research, development and distribution of medicines for rare and complex diseases. The company also provides individualized and customized services to meet and accommodate the needs of physicians and patients across Europe, the Middle East & Asia. Currently AOP...

Rebiotix Inc.

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for th...

Lumos Pharma, Inc.

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and is funded by leading healthcare investors, including Deerfield, NEA, Clarus,...

Maas Biolab LLC

Maas Biolab is a private pharmaceutical company in Albuquerque, N.M., USA, developing Mitogard®, the only cyclosporine formula designed for CSF delivery, to treat amyotrophic lateral sclerosis. Maas Biolab holds FDA Orphan Drug Designation for cyclosporine to treat ALS and world patents for cyclosporine neuroprotection against chronic neurological disea...

S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug ...

Orphan Medical Incorporated

Orphan Medical Incorporated is a development stage company, was formed to acquire, develop and market products of high medical value intended to address inadequately treated or uncommon diseases of well-defined patient populationstreated by health care specialists. A drug has high medical value if it offers a major improvement in the safety or efficacy of patient treatment and has no substantially...

TRACT Therapeutics, Inc.

TRACT Therapeutics, Inc. is a clinical-stage biotechnology company developing a novel therapeutic approach to restoring immune balance in transplantation and autoimmune disease. It’s proprietary platform technology, using autologous, polyclonally expanded T-regulatory cells was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, P...

Biovest International, Inc.

Biovest International, Inc. is an emerging leader in the field of active personalized immunotherapies targeting life-threatening cancers of the blood system. Developed in collaboration with the National Cancer Institute, BiovaxID® is a patient-specific, cancer vaccine, demonstrating statistically significant Phase III clinical benefit by prolonging dise...

EntreMed Incorporated

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s goal is to develop and commercialize therapeutics based on the Company...

Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a world leader in discovery and development of novel small interfering RNA, or siRNA, therapeutics for unmet medical needs. RNA interference is a biological process in which RNA molecules regulate expression of targeted genes. Quark’s fully integrated drug discovery and development platform spans the process from therape...

Santhera Pharmaceuticals Holding Ltd

Santhera Pharmaceuticals is a Swiss biopharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases. Santhera’s vision is to become the leading specialty pharmaceuticals company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indic...

GelTex Incorporated

We are dedicated to having a positive effect on the lives of people living with illness and disease. We have demonstrated this by bringing important new therapies from discovery to market. GelTex’s first product, Renagel® brand sevelamer hydrochloride, was granted marketing approval by the U.S. Food and Drug Administration (FDA) in October 1998 for the reduction of serum phosphorus in hemodialy...

Atlantic Healthcare plc

Atlantic Healthcare is an international specialty pharmaceutical company focussed on diseases of the gastrointestinal tract and Inflammatory Bowel Disease (IBD). The Company's lead product is alicaforsen enema, in Phase 3 development for pouchitis, and in preparation for Phase 3 clinical development for Ulcerative Colitis. Alicaforsen is also generating ea...

Orphan Europe (UK) Ltd.

Orphan Europe was started with the objective of providing orphan drugs to patients afflicted by rare disorders.Over the years an information network has been established to increase the awareness about rare disorders among healthcare professionals. The company has committed itself to provide support necessary to those working in this field. This is achieved through an extensive collaboration with ...

CepTor Corporation

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan ...

NPS Pharmaceuticals

NPS Pharmaceuticals is engaged in the discovery, development and commercialization of therapeutic small molecules and recombinant proteins to treat bone and mineral, gastrointestinal and central nervous system disorders. History of Successful Drug Discovery NPS has a history of successful drug discovery. With one approved product on the market and several more in development, NPS's discovery capab...

Inhibitex

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel antibody-based products for the prevention and treatment of serious bacterial and fungal infections in the hospital setting. We currently have two product candidates in clinical development and four product candidates in preclinical development. Our product candidates have been developed based u...

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charco...


More From BioPortfolio on "Curtana granted Orphan designation gliomas treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks